Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Dwight Moxie Biography and Net Worth

SVP of Revance Therapeutics

Dwight Moxie joined Revance in 2020 as Corporate Secretary to the Board and as Senior Vice President, General Counsel & Corporate Secretary on the Senior Executive Team. Mr. Moxie leads all legal, governance, and compliance initiatives for Revance.

Mr. Moxie brings extensive legal experience in the biopharma and healthcare sectors, advising and supporting companies developing and commercializing novel drugs. Prior to Revance, he served as the Vice President, Deputy General Counsel at Ultragenyx where he oversaw commercial operations, litigation, research & development and regulatory matters. In this position, Mr. Moxie advised on pharmaceutical education and product marketing activities, including DTC advertisements, improved review systems to support product launches and counseled on matters including clinical trials, labeling and more. Prior to Ultragenyx, he served in various legal counsel positions at Allergan and GlaxoSmithKline.

Mr. Moxie holds a J.D. degree from Howard University School of Law and a Bachelor of Arts in Social Science from Florida State University.

What is Dwight Moxie's net worth?: The estimated net worth of Dwight Moxie is at least $425,848.35 as of March 18th, 2024. Mr. Moxie owns 137,815 shares of Revance Therapeutics stock worth more than $425,848 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Moxie may own. Additionally, Mr. Moxie receives an annual salary of $713,820.00 as SVP at Revance Therapeutics. Learn More about Dwight Moxie's net worth.
How old is Dwight Moxie?: Mr. Moxie is currently 48 years old. There are 4 older executives and no younger executives at Revance Therapeutics. The oldest executive at Revance Therapeutics is Mr. Mark J. Foley, CEO & Director, who is 59 years old. Learn More on Dwight Moxie's age.
What is Dwight Moxie's salary?: As the SVP of Revance Therapeutics, Inc., Mr. Moxie earns $713,820.00 per year. There are 2 executives that earn more than Mr. Moxie. The highest earning executive at Revance Therapeutics is Mr. Mark J. Foley, CEO & Director, who commands a salary of $1,260,000.00 per year. Learn More on Dwight Moxie's salary.
How do I contact Dwight Moxie?: The corporate mailing address for Mr. Moxie and other Revance Therapeutics executives is 7555 GATEWAY BLVD., NEWARK CA, 94560. Revance Therapeutics can also be reached via phone at (615) 724-7755 and via email at [email protected]. Learn More on Dwight Moxie's contact information.
Has Dwight Moxie been buying or selling shares of Revance Therapeutics?: Dwight Moxie has not been actively trading shares of Revance Therapeutics over the course of the past ninety days. Most recently, Dwight Moxie sold 8,125 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $5.04, for a transaction totalling $40,950.00. Following the completion of the sale, the insider now directly owns 137,815 shares of the company's stock, valued at $694,587.60. Learn More on Dwight Moxie's trading history.
Who are Revance Therapeutics' active insiders?: Revance Therapeutics' insider roster includes Mark Foley (CEO), Dwight Moxie (SVP), Aubrey Rankin (Insider), Angus Russell (Director), and Tobin Schilke (CFO & Principal Accounting Officer ). Learn More on Revance Therapeutics' active insiders.
Are insiders buying or selling shares of Revance Therapeutics?: In the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 29,089 shares worth more than $143,642.48. The most recent insider tranaction occured on April, 16th when insider Erica Jordan sold 2,392 shares worth more than $9,089.60. Insiders at Revance Therapeutics own 5.1% of the company. Learn More about insider trades at Revance Therapeutics.
Information on this page was last updated on 4/16/2024.

Dwight Moxie Insider Trading History at Revance Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Sell	8,125	$5.04	$40,950.00	137,815
9/5/2023	Sell	23,853	$17.81	$424,821.93	55,066
5/15/2023	Sell	21,401	$34.55	$739,404.55	69,165
3/9/2023	Sell	18,496	$31.59	$584,288.64	55,547
9/14/2022	Sell	11,000	$27.07	$297,770.00	31,694
9/27/2021	Sell	1,675	$30.00	$50,250.00

Dwight Moxie Buying and Selling Activity at Revance Therapeutics

Revance Therapeutics Company Overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Today's Range

Now: $3.09

$3.07

$3.09

50 Day Range

MA: $4.34

$3.03

$5.92

2 Week Range

Now: $3.09

$2.30

$9.74

Volume

3,458,729 shs

Average Volume

2,819,810 shs

Market Capitalization

$322.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Find out details on these three critical Nvidia partners immediately.

Dwight Moxie Biography and Net Worth

What is Dwight Moxie's net worth?

How old is Dwight Moxie?

What is Dwight Moxie's salary?

How do I contact Dwight Moxie?

Has Dwight Moxie been buying or selling shares of Revance Therapeutics?

Who are Revance Therapeutics' active insiders?

Are insiders buying or selling shares of Revance Therapeutics?